Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity
Science Advances | January 30, 2020 | Volume: 6 | Issue: 5 | Pages: No page available
10.1126/sciadv.aay2939
| PMID 32064346
RXRA is an endothelial- and early stage–predominant therapeutic target for treating anthracycline-induced cardiotoxicity.